The fund raising by the Sophia Antipolis-based biotech company will enable it to market its treatment for Crohn’s disease
TxCell, with its head office in Sophia Antipolis, has just announced that it has raised €16.2M after its floatation on the French stock exchange.
The company, specializing in immunotherapy for the treatment of chronic inflammatory auto-immune diseases, was supported by the company’s key shareholders, Auriga Partners, Seventure and Innobio and by Bpifrance Participations who subscribed to the capital increase for the amounts of €5.7M and €8.1M respectively.
TxCell makes this type of innovative cell therapy economically viable for the first time. Using the patient’s own cells it treats chronic and severe inflammatory and auto-immune diseases. “TxCell’s listing on Euronext in Paris is a major step in accelerating the company’s development and its next-generation cell-therapies”, confirmedDamian Marron, the company’s Chief Executive Officer, in a press release.
This new type of treatment could “change the life of thousands of refractory patients suffering from inflammatory auto-immune diseases such as Crohn’s disease” he added.
Source: Team Cote d’Azur